Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02768701
Title Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors UNC Lineberger Comprehensive Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Cyclophosphamide + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.